In the JSCIC,\u30bb\u30eb\u30ec\u30fc\u30b7\u30e7\u30f3 \u30bb\u30eb\u30bb\u30e9\u30d4\u30fc\u30ad\u30c3\u30c8 SUI has been indicated as a covered item under insurance category C2 with a provisional reimbursement price of 860,000 yen, and the formal coverage date is scheduled for December 1, 2026. We plan to disclose the final decision based on the deliberation results and the notice\/notification procedures.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3750","jir_company_name":"ADR Biomedical Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/3750-20260917-01.pdf","jir_short_summary":"In the JSCIC,\u30bb\u30eb\u30ec\u30fc\u30b7\u30e7\u30f3 \u30bb\u30eb\u30bb\u30e9\u30d4\u30fc\u30ad\u30c3\u30c8 SUI has been indicated as a covered item under insurance category C2 with a provisional reimbursement price of 860,000 yen, and the formal coverage date is scheduled for December 1, 2026. We plan to disclose the final decision based on the deliberation results and the notice\/notification procedures.","jir_summary":"### Section heading\nADR Therapeutics Inc. has received manufacturing and sales approval for\u30bb\u30eb\u30ec\u30fc\u30b7\u30e7\u30f3 \u30bb\u30eb\u30bb\u30e9\u30d4\u30fc\u30ad\u30c3\u30c8 SUI, which was listed in the JSCIC deliberation materials and preliminarily categorized under insurance coverage as C2 (new function\/new technology). The provisional reimbursement price is expected to be 860,000 yen, with cost calculation method and K019-2 \u201cAutologous fat injection\u201d under 50 mL, 1st case treated as a corresponding technology fee. The formal insurance coverage timing is scheduled for December 1, 2026. Going forward, final determination will be made after deliberation results and Ministry of Health, Labour and Welfare notices; after coverage, post-marketing surveillance (PMS) will be conducted for all cases. The direct impact on performance is under assessment, and additional information will be disclosed if available.\n\n### Section 2 heading\nAs next steps toward formal coverage decision, once the JSCIC deliberation results and MOH notices are finalized, the exact start date of coverage will be formally confirmed. After coverage, PMS is conditioned, and the impact on sales and profit from market introduction remains undecided at this time. Current disclosure pertains to deliberation status and future disclosure policy.","jir_financial_highlights":"Insurance reimbursement price (provisional): 860,000 yen (Unknown)\nOfficial insurance coverage timing: Scheduled for December 1, 2026 (Unknown)","jir_category":"","jir_hashtags":"#ADRBiomedicals, #InsuranceCoverage, #JSCICDeliberation","jir_key_figures":"Insurance reimbursement price (provisional): 860,000 yen\nOfficial insurance coverage timing: Scheduled for December 1, 2026\nApplicable technology fee: K019-2 \u201cAutologous fat injection\u201d under 50 mL, 1st case 22,900 points","jir_meta_title":"ADR Biomedicals Holdings \u2014 Deliberation Progress Toward Insurance Coverage Decision | SUI Price Proposal and Coverage Timing","jir_meta_description":"Outline of the JSCIC deliberation progress and provisional price, and planned timing of formal coverage for\u30bb\u30eb\u30ec\u30fc\u30b7\u30e7\u30f3 \u30bb\u30eb\u30bb\u30e9\u30d4\u30fc\u30ad\u30c3\u30c8 SUI, developed by ADR Biomedicals Holdings\u2019 subsidiary. Key points on future deliberations and disclosure policy.","jir_og_title":"Deliberation Progress Toward Insurance Coverage Decision |\u30bb\u30eb\u30bb\u30e9\u30d4\u30fc\u30ad\u30c3\u30c8 SUI","jir_og_description":"Announcement of the provisional coverage category C2 and reimbursement price for\u30bb\u30eb\u30ec\u30fc\u30b7\u30e7\u30f3 \u30bb\u30eb\u30bb\u30e9\u30d4\u30fc\u30ad\u30c3\u30c8 SUI, with formal coverage date aimed for December 1, 2026. Final decision depends on future deliberations.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59366,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-114958","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n